Daihong Liu

This study tests whether adding the drug ruxolitinib to standard steroids works better than steroids alone for severe graft-versus-host disease (GVHD) after a stem cell transplant. About 54 adults who recently developed severe GVHD will take part. The goal is to see if the combo …

This study tests whether adding the drug ruxolitinib to standard steroids works better than steroids alone for treating grade II acute graft-versus-host disease (GVHD), a common complication after stem cell transplants. About 168 adults who have had a stem cell transplant for blo…

This study tests a new treatment for people with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment uses special particles to deliver mRNA into the body to create CAR-T cells that target two markers on cancer cells. The goal is to se…

This study tests whether adding two drugs—chidamide and a PD-1 inhibitor—after CAR-T cell therapy can help prevent relapse in people with aggressive B-cell lymphoma that has come back or not responded to treatment. About 30 participants will receive this maintenance therapy to se…

This study tests a new treatment called PD-1Ab21-BCMA CAR-T cells for people with multiple myeloma who also have kidney problems. The therapy uses the patient's own immune cells, modified to better find and attack cancer cells. The goal is to see if this treatment can keep the ca…

This study tests a new treatment for Epstein-Barr virus (EBV) infection that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to find and attack the virus. About 18 adults who have had a stem cell transplant and still …

This study tests a new treatment called EBV-AST cells for people who have an EBV virus infection after a stem cell transplant. The goal is to find the safest dose and see if it can clear the virus from the blood. About 18 adults aged 18-75 will take part. The treatment uses speci…

This early-phase study is testing an experimental cell therapy called EBV-AST for people with Epstein-Barr virus (EBV)-related lymphoproliferative disorders, including certain lymphomas and post-transplant complications. About 18 adults will receive up to three infusions of the t…